Comparing GLP-1 Medications: Which Works Best?

Key Takeaways

A 2025 network meta-analysis found that tirzepatide produced the greatest weight reduction among liraglutide, semaglutide, and tirzepatide, though all three demonstrated meaningful efficacy for overweight and obesity.
Real-world evidence generally aligns with randomized trial findings for incretin-based therapies, but outcomes can vary more widely outside of controlled study conditions.
Weight regain after stopping these medications is common, underscoring that obesity is a chronic, multisystem disease that often requires long-term management strategies.
GLP-1 receptor agonists are being studied for uses beyond weight loss, including potential applications in reproductive health and oncology, though these remain investigational.
Baseline hormone levels such as fasting GLP-1 and GIP may not reliably predict how well an individual will respond to semaglutide or tirzepatide, according to recent research.

What Are the Main GLP-1 Medications Available?

Several GLP-1 medications are currently available, with semaglutide and tirzepatide being the most widely used options for weight loss in adults — and the research shows they differ meaningfully in how they work and how much weight people tend to lose on them.

How these medications work

GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces after eating. It signals fullness to your brain, slows digestion, and helps regulate blood sugar. GLP-1 medications mimic or amplify that signal. Some target only the GLP-1 receptor; others activate additional hormone receptors simultaneously.

The main options

Liraglutide (brand name: Saxenda) — A daily injection that was one of the first GLP-1 medications approved specifically for weight management. Research shows it produces meaningful but more modest weight loss compared to newer options, according to a 2025 network meta-analysis.
Semaglutide (brand names: Wegovy for weight loss; Ozempic for type 2 diabetes) — A once-weekly injection. The same drug, different doses, different approvals. The 2025 meta-analysis found semaglutide produces greater average weight loss than liraglutide. Researchers are also studying semaglutide in areas well beyond weight loss, including reproductive health, as one 2025 review notes — though those uses are not yet standard care.
Tirzepatide (brand names: Zepbound for weight loss; Mounjaro for type 2 diabetes) — Also a once-weekly injection. Tirzepatide is a dual agonist, meaning it activates two hormone receptors — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — rather than one. That dual action appears to matter. The 2025 meta-analysis found tirzepatide produced the greatest average weight loss of the three medications studied.

A quick comparison

Medication	Injection frequency	Receptors targeted	Relative weight loss*
Liraglutide	Daily	GLP-1	Modest
Semaglutide	Weekly	GLP-1	Moderate–high
Tirzepatide	Weekly	GLP-1 + GIP	Highest studied

*Based on network meta-analysis findings; individual results vary.

Stopping any of these medications tends to reverse much of the weight lost. A 2025 systematic review found significant weight regain after people stopped taking GLP-1 and related medications. That’s a conversation worth having with your doctor before you start.

Not medical advice. This content is for general informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

How Do Liraglutide, Semaglutide, and Tirzepatide Compare for Weight Loss?

All three medications produce meaningful weight loss, but they are not equal — tirzepatide tends to produce the greatest average weight reduction, followed by semaglutide, then liraglutide, based on current clinical evidence.

A 2025 systematic review and network meta-analysis compared all three drugs head-to-head using data pooled across multiple trials. The findings:

Liraglutide (brand name Saxenda, injected daily) produced the most modest average weight loss of the three. It works by mimicking one gut hormone — GLP-1 — that signals fullness to the brain.
Semaglutide (brand names Wegovy for weight loss, Ozempic for diabetes, injected weekly) produced significantly greater weight loss than liraglutide. Like liraglutide, it targets the GLP-1 receptor, but its longer-acting design means one weekly injection does the job.
Tirzepatide (brand name Zepbound for weight loss, Mounjaro for diabetes, injected weekly) produced the greatest average weight loss of the three. It targets two gut hormones — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — which may explain its stronger effect on appetite and body weight, according to the same meta-analysis.

Why the numbers matter — and why they don’t tell the whole story.

Averages hide a wide range of individual responses. Real people lose more or less than the trial averages, and real-world evidence shows that results outside of tightly controlled clinical trials can look quite different from published study data. Your starting weight, other health conditions, the dose you can tolerate, and how long you stay on the medication all shape your outcome.

Stopping matters, too. A meta-analysis on weight regain found that people regain a substantial portion of lost weight after discontinuing these medications — a pattern seen across all three drugs. Weight loss with GLP-1 medications is generally tied to continued use.

Side effects — most commonly nausea, vomiting, and digestive discomfort — are common to all three, though their frequency and intensity vary by drug and dose, as the efficacy and safety review documents.

The “best” medication is the one that works safely for you. A prescribing clinician can weigh your health history, insurance coverage, and personal tolerance to help you choose.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare professional. Never start, stop, or change a medication without guidance from your doctor or pharmacist.

How Do Real-World Results Differ From Clinical Trial Results?

Real-world weight loss with these medications typically reaches half to two-thirds of what clinical trial participants achieve. That gap exists for concrete reasons, and understanding them helps you set realistic expectations.

Clinical trials operate under near-perfect conditions. Participants are carefully screened, closely monitored, and supported with regular check-ins, structured diet guidance, and lifestyle coaching throughout the study. Everyday care rarely offers that level of support. Real-World vs. Randomized Trial Evidence confirms this pattern directly: real-world outcomes for GLP-1 medications consistently fall short of the results reported in randomized controlled trials (RCTs — studies where participants are randomly assigned to a treatment or a placebo).

Several specific factors drive that gap:

Who gets included. Trial participants are selected to be relatively healthy aside from their weight. People with multiple health conditions, certain medications, or other complicating factors are often excluded. In real life, those people are exactly who ends up on these medications.
How consistently the medication is taken. Trials track adherence (meaning, whether people actually take their doses as prescribed) very carefully. Real-world patients miss doses, pause treatment due to cost or supply issues, or stop earlier than planned.
Lifestyle support. Trial participants receive structured coaching. Most real-world patients do not get the same intensity of dietary and behavioral support alongside their prescription.
Dose adjustments. Trials follow strict dosing schedules. In practice, providers sometimes keep patients at lower doses longer to manage side effects, which can reduce the total weight lost.

Biology plays a role too. Research on GLP-1 and GIP hormone levels suggests that individual differences in how your body responds to these medications shape your results — meaning two people on the same drug and dose can have meaningfully different outcomes.

Weight regain after stopping is another real-world reality that trials sometimes underemphasize. A systematic review on post-cessation regain found that people regain a substantial portion of lost weight after discontinuing these medications, which points to obesity as an ongoing condition rather than one with a fixed endpoint — a point reinforced by research framing obesity as a multisystem disease.

The medications work. Your results will be shaped by your whole situation — not just the drug.

This content is for general informational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting, changing, or stopping any medication.

What Happens to Your Weight If You Stop Taking These Medications?

Most people who stop taking a GLP-1 medication regain a significant portion of the weight they lost — often within months. Research shows this is not a personal failure; it reflects how these medications work and what obesity actually is as a condition.

GLP-1 medications (drugs like semaglutide and tirzepatide that mimic a natural gut hormone to reduce appetite and slow digestion) help your body maintain a lower weight while you take them. Stop the medication, and those effects stop too. Your appetite signals return to where they were before. For many people, that means hunger comes back — and weight follows.

A systematic review and meta-analysis looking specifically at weight regain after stopping weight-management medications found that patients regained a substantial proportion of their lost weight after discontinuation. The regain was not immediate, but it was consistent across studies.

The evidence breaks down into key points:

Regain is common and measurable. The post-cessation meta-analysis found that weight regain after stopping these medications is a predictable pattern, not an outlier experience.
Obesity is a chronic condition. A research review on obesity as a multisystem disease explains that obesity involves long-term changes in metabolism, hormones, and brain signaling — meaning it often requires ongoing management, much like high blood pressure or diabetes.
The medication is doing active work. GLP-1 drugs reduce appetite and change how your body processes food signals. When you stop, those changes reverse. The weight was not “fixed.” It was managed.
Real-world results mirror clinical trials on this point. A narrative review comparing real-world and trial evidence confirms that outcomes seen in controlled studies — including regain after stopping — also appear in everyday clinical practice.

Weight regain does not mean the medication failed you. It means the medication was working, and now it isn’t there anymore. That distinction matters.

If you are thinking about stopping your medication — whether because of cost, side effects, or a personal choice — talk with your prescribing provider first. They can help you plan a strategy that protects the progress you have made.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your medications or health conditions.

Who Else Might Benefit From GLP-1 Medications Beyond Weight Loss?

GLP-1 medications may benefit people well beyond weight loss alone — researchers are actively studying their effects on heart health, blood sugar, kidney function, liver disease, and even certain reproductive conditions. The weight-loss benefits get the most attention, but the science points to a much wider picture.

Here is what the current evidence shows:

Heart and blood vessel health. Obesity strains the entire cardiovascular system. One research review describes obesity as a multisystem disease — meaning it affects the heart, blood vessels, kidneys, and metabolism all at once, not just body weight. GLP-1 medications appear to address several of those systems simultaneously by reducing the metabolic stress that damages them.
Type 2 diabetes and blood sugar control. GLP-1 drugs were originally developed for diabetes, not weight loss. They work by prompting the pancreas to release insulin when blood sugar rises. Real-world studies confirm that people with type 2 diabetes using these medications see meaningful improvements in blood sugar control outside of clinical trial settings.
Liver disease (MASLD/MASH). MASLD stands for metabolic dysfunction-associated steatotic liver disease — a condition where excess fat builds up in the liver. Emerging research links obesity-related metabolic changes to liver damage, and GLP-1 medications are being studied as a potential treatment for this condition.
Kidney protection. The kidneys take a hit from both obesity and high blood sugar over time. Researchers reviewing obesity as a multisystem disease identify kidney function as one of the organ systems that may benefit from GLP-1 treatment, though this area is still being studied.
Reproductive health. This one surprises many people. A 2025 research paper explores semaglutide and tirzepatide’s potential roles in conditions like polycystic ovary syndrome (PCOS) — a hormonal condition that affects fertility — and notes early-stage research into their effects on reproductive outcomes. The evidence here is preliminary. Promising, but early.
Adolescents with obesity. Adults are not the only ones being studied. A review of GLP-1 use in pediatric obesity found that these medications show effectiveness and an acceptable safety profile in adolescents, though this remains a specialized area requiring close medical supervision.

The common thread across all of these? Obesity itself drives damage across multiple body systems, and treating it — through whatever safe, effective means works for a given person — can create ripple effects that reach far beyond the number on the scale.

This content is for general informational purposes only and is not medical advice. Talk with a qualified healthcare provider before starting, stopping, or changing any medication or treatment.

What Should You Ask Your Doctor Before Starting a GLP-1 Medication?

Before starting a GLP-1 medication, bring a list of specific questions to your appointment — your doctor needs details about your full health picture to help you use these drugs safely and set realistic expectations. The questions below give you a practical starting point.

Going in prepared makes a real difference. GLP-1 medications (short for glucagon-like peptide-1 receptor agonists — drugs that mimic a natural gut hormone to reduce appetite and slow digestion) are not one-size-fits-all, and the conversation with your doctor matters as much as the prescription itself.

Ask about which medication fits your situation

Different GLP-1 options exist. Liraglutide, semaglutide, and tirzepatide each carry a different weight-loss profile and side-effect pattern, and a 2025 network meta-analysis found meaningful differences in both how well they work and how people tolerate them. Your doctor can walk you through the options and explain why one fits your health history better than another.

Ask what results are realistic — and when

Results vary. Ask your doctor what a reasonable outcome looks like for you, not for a clinical trial average. Real-world results diverge from trial results, and a narrative review of real-world versus trial evidence confirms that gap exists. Short. Honest. Worth knowing upfront.

Ask what happens if you stop

This one surprises many people. A systematic review and meta-analysis on post-cessation weight regain (source) found that people commonly regain a significant portion of lost weight after stopping these medications. Your doctor can explain how long you might need to stay on treatment and what a long-term plan looks like.

Ask about your other health conditions and medications

GLP-1 drugs interact with your whole body — not just fat tissue. Research framing obesity as a multisystem disease underscores why your doctor needs your complete medical history before prescribing. Tell them everything: diabetes, thyroid conditions, digestive disorders, fertility plans, and every supplement or medication you take.

A practical question checklist to bring with you:

Which GLP-1 medication do you recommend for me, and why that one specifically?
What side effects should I watch for in the first few weeks?
How will we measure whether this is working?
What is the plan if I need to stop — either by choice or because of side effects?
Does my insurance cover this, and what are the out-of-pocket costs if not?
How does this fit with my other prescriptions?

Your doctor is your partner here. Come curious, come honest, and come with your questions written down.

Not medical advice. This content is for general informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.

FAQ

Is tirzepatide stronger than semaglutide for weight loss?

A 2025 systematic review and network meta-analysis published in the Journal of Endocrinological Investigation found that tirzepatide was associated with greater weight reduction compared to semaglutide and liraglutide. However, individual responses vary, and the best medication for any person depends on their health history, tolerability, and goals — something only a qualified healthcare provider can assess.

Will I regain weight if I stop taking a GLP-1 medication?

Research suggests that weight regain after stopping GLP-1-based weight management medications is common. A 2025 systematic review and meta-analysis in Cureus found that a significant portion of lost weight tends to return after discontinuation, which is consistent with the understanding that obesity is a chronic condition often requiring ongoing treatment.

Can my fasting hormone levels predict how well I’ll respond to semaglutide or tirzepatide?

A study published in Diagnostics (2025) investigated whether fasting GLP-1 and GIP levels could predict initial pharmacological response to these medications. The findings suggest that baseline fasting incretin levels may not be reliable predictors of individual response, meaning other clinical factors are likely more important in guiding treatment decisions.

Are GLP-1 medications being studied for uses other than weight loss?

Yes. A 2025 review in Biomedicines examined emerging or ‘unconventional’ applications of semaglutide and tirzepatide, including potential roles in oncology and human reproduction. These applications are still investigational and not established treatments — always consult a healthcare professional about approved uses.

Are GLP-1 medications appropriate for children or teenagers with obesity?

A 2025 review in Digestive and Liver Disease examined GLP-1 receptor agonists in pediatric obesity and noted growing interest in their use for younger populations. However, approvals, dosing, and safety considerations differ from adults, and any decisions about medication use in children must be made by a qualified pediatric healthcare provider.

How common is interest in GLP-1 medications among the general public?

A 2025 survey-based study published in the International Journal of Obesity, conducted among a representative sample of Finnish adults, found notable levels of both current use and interest in GLP-1 medications, reflecting growing public awareness of these treatments for weight management.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.